
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx is on a path towards stabilization and improved profitability under the newly appointed leadership team, as demonstrated by their Q3 results with revenue growth and improved margins. Their focus on costs, margins, and operational discipline, along with a new credit facility, suggests a potential for sustainable profitability in the future. However, their future success will depend on their ability to increase treatment center utilization and patient conversion in the US without significantly expanding their sales force. Ultimately, Pulmonx has the potential for long-term growth in the minimally-invasive treatment market for severe emphysema patients.
Bears say
Pulmonx is facing numerous risks, including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks. These risks, along with declining sales in the US and high operating expenses, resulted in a net loss of $54.0M in 2025. Upcoming earnings will be an important indicator of the company's future performance.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares